Maverick Advocaten in FD about ACM’s oversight efforts regarding (expensive) prescription drugs

The Netherlands Authority for Consumers and Markets (ACM) announced that the prices of prescription drugs is one of the four priorities on ACM’s agenda in 2018-2019. ACM published an ACM Working Paper: ‘Reconciling competition law and IP law: the case of patented pharmaceuticals and dominance abuse’, see here. Diederik Schrijvershof provided his opinion in an article in Het Financieele Dagblad about the heightened attention of ACM for producers of prescription drugs and abuse of dominance. You can find the article here (in Dutch). On 12 April 2018, Diederik Schrijvershof speaks about ACM’s and the European Commission’s oversight efforts regarding (expensive) prescription drugs. For more information about the supervision of ACM and the European Commission  in the pharma and healthcare sector, read this blog.

Follow Maverick Advocaten on Twitter and LinkedIn

Contact details

Diederik Schrijvershof

T +31 20 238 20 03
M +31 6 81 364 318